Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs SGM 1019 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Second Genome
  • Most Recent Events

    • 05 Feb 2019 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
    • 23 Jan 2019 Status changed from not yet recruiting to recruiting, according to a Second Genome media release.
    • 23 Jan 2019 According to a Second Genome media release, Stephen Harrison, Medical Director of Pinnacle Clinical Research, is the Principal Investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top